Login to Your Account



Clinic Roundup


Friday, March 2, 2012
• Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said it started a Phase II study of NX-1207 in low-grade localized prostate cancer. The study is expected to enroll 150 men in a two-dose, six-week design. NX-1207 currently is in Phase III testing for benign prostatic hyperplasia, but preclinical studies have shown that the drug also has activity against prostate cancer cells when administered at higher dosage levels.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription